IMMUPHARMA PLC

Director's Dealing • Sep 1, 2025

National Storage Mechanism | Additional information

RNS Number : 5047X

Immupharma PLC

01 September 2025

ImmuPharma PLC

("ImmuPharma" or the "Company")

Appointments of Chief Scientific Officer and Head of R&D

ImmuPharma PLC (LSE: IMM), a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics , announces key appointments, in conjunction with the filing of a groundbreaking new patent application for its lead asset P140, separately announced today.

Recognising the significance of this major step forward, Dr Sébastien Goudreau has been promoted into the position of Chief Scientific Officer and Dr Laura Mauran-Ambrosino has been promoted to Head of Research and Development, of the Company.

Commenting on this announcement, Tim McCarthy, CEO of ImmuPharma, said:

"The new patent on P140 is a major step forward for the Company and is the result of the impressive and dedicated research conducted by both by Sébastien and Laura over the last two years.

As we continue to move forward on the next step of our corporate journey, which is the partnering and commercialisation of our product portfolio, P140 in particular, it is important that our R&D team is at the forefront of our interactions and negotiations with current and future commercial partners.

I and the Board congratulate both Sébastien and Laura on their new appointments and thank them for their innovation and hard work."

Ends

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended.  On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

For further information please contact:

ImmuPharma PLC ( www.immupharma.co.uk ) Tim McCarthy, Chief Executive Officer Lisa Baderoon, Head of Investor Relations	+44 (0) 207 206 2650 + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD) Neil Baldwin Stanford Capital Partners (Joint Broker) Patrick Claridge, Bob Pountney SI Capital (Joint Broker) Nick Emerson	+44 (0) 203 36 8 3550 +44 (0) 20 3650 3650 +44 (0) 1483 413500

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.

For additional information about ImmuPharma please visit www.immupharma.co.uk .

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCEADNFEEXSEFA